Understanding how metabolism affects lung cell changes in fibrosis
Metabolic Regulation of Myofibroblast Differentiation
This study is looking at how changes in the way lung cells use energy might lead to the thickening and scarring of lungs in people with Idiopathic Pulmonary Fibrosis (IPF), with the hope of finding new ways to help treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10810708 on NIH RePORTER |
What this research studies
This research investigates the role of metabolic processes in the differentiation of lung fibroblasts into myofibroblasts, which are key players in the development of Idiopathic Pulmonary Fibrosis (IPF). By examining how these cells alter their metabolism, particularly through glycolysis and the production of glycine, the research aims to uncover new mechanisms that contribute to lung fibrosis. The study will identify the signaling pathways and regulators involved in this metabolic reprogramming, which could lead to innovative treatment strategies for IPF. Patients with IPF may benefit from insights gained into how metabolic changes drive their disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Idiopathic Pulmonary Fibrosis.
Not a fit: Patients with other forms of lung disease or those without a diagnosis of pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for treating Idiopathic Pulmonary Fibrosis, potentially improving patient outcomes.
How similar studies have performed: While the specific metabolic pathways in myofibroblasts are being explored in this research, similar studies have shown promise in understanding fibrosis mechanisms, indicating potential for success.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Hamanaka, Robert Brian — University of Chicago
- Study coordinator: Hamanaka, Robert Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.